Advancing Knowledge. Enhancing Care.
Advancing Knowledge. Enhancing Care.

Psoriasis News

the latest news from ipc, industry and others

EADV 2020 | A Phase 2B, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Assessing the Efficacy, Safety, and Tolerability of Sonelokinab (M1095), an IL-17A/F Nanobody, in Patients with Moderate-to-severe Chronic Plaque Psoriasis: Results from 24 Weeks

Biologics 2020

Presented by Kim A. Papp, MD, PhD

A report from the 29th Congress of the European Academy of Dermatology and Venereology

Intro and design: Sonelokinab is an IL-17 A/F nanobody. This study assessed PASI-90 and IGA(0,1) response of sonelokinab at various doses and schedules, versus placebo and secukinumab

Results: For sonelokinab, PASI-90 response was achieved in approximately 33% (week 4) and 80% (week 12) and was sustained to week 24.

PASI-100 was achieved by roughly 50% by week 24. IGA 0,1 response in approximately 80% (week 12) and was sustained in responders to week 24. Secukinumab showed similar response, but sonelokinab response was more rapid.

Adverse effects: Non-serious oral candidiasis occurred with IL-17 blockade. There were few serious AEs, no major adverse cardiovascular events, and no deaths at week 24.

Conclusion: Sonelokinab appears promising, with rapid and durable response.


Filter by Topic:

We use cookies on this site to enhance your online experience. By continuing to use this site, you agree to accept cookies.